Emergent Biosolutions (EBS)

$8.50 -0.45 (-5.03%)
Market Cap 462.21M
Revenue (ttm) 742.90M
Net Income (ttm) 52.60M
EPS (ttm) N/A
PE Ratio 9.50
Forward PE N/A
Profit Margin 7.08%
Debt to Equity Ratio 1.10
Volume 606,400
Avg Vol 800,638
Day's Range N/A - N/A
Shares Out 51.64M
Stochastic %K 45%
Beta 2.33
Analysts Strong Sell
Price Target $12.00

Company Profile

Emergent BioSolutions Inc., a life sciences company, provides preparedness and response solutions for accidental, deliberate, and naturally occurring public health threats in the United States, Canada, and internationally. It operates through Commercial Products, MCM Products, and All Other Revenues segments. The company offers ACAM2000, a smallpox and mpox vaccine; Anthrax Immune Globulin Intravenous (ANTHRASIL), a polyclonal antibody therapeutic for the treatment of inhalational anthrax; Botul...

Industry: Drug Manufacturers - Specialty & Generic
Sector: Healthcare
Phone: 240 631 3200
Fax: 240 631 3203
Address:
300 Professional Drive, Suite 400, Gaithersburg, United States
ComradeKomisar
ComradeKomisar May. 13 at 3:31 PM
$EBS judging from the spikes in borrow rates at IBKR, shorting frequency has been super agressive since last opex. However, they never managed to get it below the 'breakup' price which is 8-ish.
0 · Reply
ImmxBeliever
ImmxBeliever May. 13 at 3:30 PM
$EBS
0 · Reply
billywilliamz
billywilliamz May. 13 at 3:27 PM
$EBS 6. Fiddy
0 · Reply
ComradeKomisar
ComradeKomisar May. 13 at 3:24 PM
$EBS Big account in X (86K followers)
0 · Reply
BavarianStallion
BavarianStallion May. 13 at 3:15 PM
$EBS can someone explain why we the management doesn‘t do buybacks on such days like hell?
0 · Reply
Unicorn2020
Unicorn2020 May. 13 at 2:14 PM
$EBS This sucker seems to get dragged back down to fill the lower gap at $6.30. Give it 90 days. It will get there.
0 · Reply
ComradeKomisar
ComradeKomisar May. 13 at 1:53 PM
$EBS Having to sell the travel vaccine portfolio was an absolute fumble by this management (the board is effectively new, so the blame passes over).
2 · Reply
ComradeKomisar
ComradeKomisar May. 13 at 1:22 PM
$EBS Gut niewuss, Jane St., a most vile shop, is almost out.
0 · Reply
billywilliamz
billywilliamz May. 13 at 1:21 PM
$EBS is this a lot ?
0 · Reply
ComradeKomisar
ComradeKomisar May. 13 at 1:19 PM
$EBS Regrettably, they/them/those ...covered.
0 · Reply
Latest News on EBS
Hantavirus cases spark surge in pharma and biotech stocks — here's why

May 11, 2026, 7:53 AM EDT - 2 days ago

Hantavirus cases spark surge in pharma and biotech stocks — here's why

INO MRNA NVAX

Emergent BioSolutions Earnings Call Transcript: Q1 2026

Apr 30, 2026, 5:00 PM EDT - 12 days ago

Emergent BioSolutions Earnings Call Transcript: Q1 2026

Emergent BioSolutions Reports First Quarter 2026 Financial Results

Apr 30, 2026, 4:30 PM EDT - 12 days ago

Emergent BioSolutions Reports First Quarter 2026 Financial Results

Emergent BioSolutions receives Singapore regulatory approval for ACAM2000

2026-04-30T13:58:59.000Z - 13 days ago

Emergent BioSolutions receives Singapore regulatory approval for ACAM2000

Emergent BioSolutions Receives Approval from Singapore Health Sciences Authority for Expanded Indication of ACAM2000® (Smallpox and Mpox (Vaccinia) Vaccine, Live) to Include Mpox

Apr 30, 2026, 7:55 AM EDT - 13 days ago

Emergent BioSolutions Receives Approval from Singapore Health Sciences Authority for Expanded Indication of ACAM2000® (Smallpox and Mpox (Vaccinia) Vaccine, Live) to Include Mpox

Emergent BioSolutions Transcript: AGM 2026

Apr 29, 2026, 9:00 AM EDT - 14 days ago

Emergent BioSolutions Transcript: AGM 2026

Emergent BioSolutions enters SAB-142 development pact with SAB Biotherapeutics

2026-04-29T12:30:52.000Z - 14 days ago

Emergent BioSolutions enters SAB-142 development pact with SAB Biotherapeutics

SABS

Emergent BioSolutions Secures Long-Term Strategic Manufacturing Contract with SAB Biotherapeutics to Advance Type 1 Diabetes Candidate, SAB-142

Apr 29, 2026, 7:35 AM EDT - 14 days ago

Emergent BioSolutions Secures Long-Term Strategic Manufacturing Contract with SAB Biotherapeutics to Advance Type 1 Diabetes Candidate, SAB-142

Emergent BioSolutions Partners with Professional Baseball Player Davis Schneider to Raise Awareness of NARCAN® Nasal Spray Among Canadians and Help Save Lives

Apr 29, 2026, 6:53 AM EDT - 14 days ago

Emergent BioSolutions Partners with Professional Baseball Player Davis Schneider to Raise Awareness of NARCAN® Nasal Spray Among Canadians and Help Save Lives

Emergent BioSolutions reports Imojev manufacturing pact with Substipharm

2026-04-28T12:59:14.000Z - 15 days ago

Emergent BioSolutions reports Imojev manufacturing pact with Substipharm

Emergent BioSolutions and Substipharm Biologics Announce Strategic Manufacturing Partnership to Support Japanese Encephalitis Vaccine in the United States

Apr 28, 2026, 8:01 AM EDT - 15 days ago

Emergent BioSolutions and Substipharm Biologics Announce Strategic Manufacturing Partnership to Support Japanese Encephalitis Vaccine in the United States

Emergent BioSolutions Successfully Refinances Term Loan, Amends Asset-backed Loan Facility and Increases Financial Flexibility

Apr 16, 2026, 4:05 PM EDT - 26 days ago

Emergent BioSolutions Successfully Refinances Term Loan, Amends Asset-backed Loan Facility and Increases Financial Flexibility

Emergent BioSolutions to Report First Quarter 2026 Financial Results on April 30, 2026

Apr 16, 2026, 4:05 PM EDT - 26 days ago

Emergent BioSolutions to Report First Quarter 2026 Financial Results on April 30, 2026

Emergent BioSolutions teams with British Columbia on Take-Home Naloxone Program

2026-04-09T20:31:33.000Z - 4 weeks ago

Emergent BioSolutions teams with British Columbia on Take-Home Naloxone Program

Emergent BioSolutions Partners with British Columbia to Supply NARCAN® Nasal Spray for the Launch of the Expanded BC Take Home Naloxone Program

Apr 9, 2026, 4:25 PM EDT - 4 weeks ago

Emergent BioSolutions Partners with British Columbia to Supply NARCAN® Nasal Spray for the Launch of the Expanded BC Take Home Naloxone Program

Emergent BioSolutions Launches New NARCAN® Nasal Spray Carrying Case and Multipacks Alongside College Campus Outreach to Expand Opioid Overdose Preparedness

Apr 7, 2026, 8:05 AM EDT - 5 weeks ago

Emergent BioSolutions Launches New NARCAN® Nasal Spray Carrying Case and Multipacks Alongside College Campus Outreach to Expand Opioid Overdose Preparedness

Emergent BioSolutions Participates in Upcoming International Preparedness Conferences

Apr 2, 2026, 8:00 AM EDT - 5 weeks ago

Emergent BioSolutions Participates in Upcoming International Preparedness Conferences

Emergent BioSolutions announces over $60M in government contract awards

2026-03-25T20:26:40.000Z - 6 weeks ago

Emergent BioSolutions announces over $60M in government contract awards

Emergent BioSolutions Secures over $60 Million in New Contract Award with the U.S. Government and New Orders with an International Government Partner for Smallpox Medical Countermeasures

Mar 25, 2026, 4:15 PM EDT - 6 weeks ago

Emergent BioSolutions Secures over $60 Million in New Contract Award with the U.S. Government and New Orders with an International Government Partner for Smallpox Medical Countermeasures

Mpox Is on the Rise. 3 Vaccine Stocks Worth a Second Look.

Mar 17, 2026, 12:49 PM EDT - 2 months ago

Mpox Is on the Rise. 3 Vaccine Stocks Worth a Second Look.

SIGA

Emergent BioSolutions price target lowered to $12 from $15 at H.C. Wainwright

2026-03-09T10:10:22.000Z - 2 months ago

Emergent BioSolutions price target lowered to $12 from $15 at H.C. Wainwright

Emergent BioSolutions appoints Fowler to board of directors

2026-03-03T13:40:58.000Z - 2 months ago

Emergent BioSolutions appoints Fowler to board of directors

Emergent BioSolutions appoints Fowler to board of directors

2026-03-03T13:27:16.000Z - 2 months ago

Emergent BioSolutions appoints Fowler to board of directors

Emergent BioSolutions Announces Appointment of John D. Fowler, Jr. to Board of Directors

Mar 3, 2026, 8:00 AM EST - 2 months ago

Emergent BioSolutions Announces Appointment of John D. Fowler, Jr. to Board of Directors

Emergent BioSolutions sees FY26 revenue $720M-$760M, consensus $809.4M

2026-02-26T22:51:12.000Z - 2 months ago

Emergent BioSolutions sees FY26 revenue $720M-$760M, consensus $809.4M

Emergent BioSolutions sees Q1 revenue $135M-$155M, consensus $275M

2026-02-26T22:45:39.000Z - 2 months ago

Emergent BioSolutions sees Q1 revenue $135M-$155M, consensus $275M

Emergent BioSolutions reports Q4 EPS (43c) vs. 5c last year

2026-02-26T22:40:37.000Z - 2 months ago

Emergent BioSolutions reports Q4 EPS (43c) vs. 5c last year

Emergent BioSolutions announces up to C$140M in Canadian contracts

2026-02-26T22:36:31.000Z - 2 months ago

Emergent BioSolutions announces up to C$140M in Canadian contracts

Emergent BioSolutions authorizes $50M stock repurchase program

2026-02-26T22:30:21.000Z - 2 months ago

Emergent BioSolutions authorizes $50M stock repurchase program

Emergent BioSolutions Earnings Call Transcript: Q4 2025

Feb 26, 2026, 5:00 PM EST - 2 months ago

Emergent BioSolutions Earnings Call Transcript: Q4 2025

Emergent BioSolutions Reports Fourth Quarter and Full Year 2025 Financial Results

Feb 26, 2026, 4:05 PM EST - 2 months ago

Emergent BioSolutions Reports Fourth Quarter and Full Year 2025 Financial Results

Emergent BioSolutions Announces Approximately $140 Million in Contract Awards with the Government of Canada, Strengthening Canada's Leadership in Health Preparedness

Feb 26, 2026, 4:01 PM EST - 2 months ago

Emergent BioSolutions Announces Approximately $140 Million in Contract Awards with the Government of Canada, Strengthening Canada's Leadership in Health Preparedness

Emergent BioSolutions Announces New $50 Million Stock Repurchase Program

Feb 26, 2026, 4:01 PM EST - 2 months ago

Emergent BioSolutions Announces New $50 Million Stock Repurchase Program

Emergent BioSolutions gets FDA approval of sNDA for Narcan

2026-02-12T23:05:22.000Z - 3 months ago

Emergent BioSolutions gets FDA approval of sNDA for Narcan

Emergent BioSolutions Receives U.S. FDA Approval of Supplemental New Drug Application (sNDA) for NARCAN® Nasal Spray Multipacks

Feb 12, 2026, 6:00 PM EST - 3 months ago

Emergent BioSolutions Receives U.S. FDA Approval of Supplemental New Drug Application (sNDA) for NARCAN® Nasal Spray Multipacks

Emergent BioSolutions to Report Fourth Quarter and Full Year 2025 Financial Results on February 26, 2026

Feb 12, 2026, 9:02 AM EST - 3 months ago

Emergent BioSolutions to Report Fourth Quarter and Full Year 2025 Financial Results on February 26, 2026

NY Attorney General Sues Former Emergent BioSolutions CEO for Insider Trading

Jan 15, 2026, 1:08 PM EST - 4 months ago

NY Attorney General Sues Former Emergent BioSolutions CEO for Insider Trading

Former Emergent BioSolutions CEO sued by NY AG for insider trading

2026-01-15T16:50:51.000Z - 4 months ago

Former Emergent BioSolutions CEO sued by NY AG for insider trading

AZN

Emergent BioSolutions Transcript: 44th Annual J.P. Morgan Healthcare Conference

Jan 14, 2026, 8:15 PM EST - 4 months ago

Emergent BioSolutions Transcript: 44th Annual J.P. Morgan Healthcare Conference

Emergent announces U.S. FDA approved sNDA for OTC NARCAN nasal spray

2026-01-14T13:05:41.000Z - 4 months ago

Emergent announces U.S. FDA approved sNDA for OTC NARCAN nasal spray

Emergent BioSolutions announces $100M paydown of term loan principal

2026-01-12T12:47:27.000Z - 4 months ago

Emergent BioSolutions announces $100M paydown of term loan principal

Emergent BioSolutions Announces $100 Million Paydown of Term Loan Principal, a Significant Step Achieved Toward its Multi-year Transformation

Jan 12, 2026, 7:30 AM EST - 4 months ago

Emergent BioSolutions Announces $100 Million Paydown of Term Loan Principal, a Significant Step Achieved Toward its Multi-year Transformation

Emergent BioSolutions receives $21.5M BioThrax order from Department of War

2026-01-08T21:45:43.000Z - 4 months ago

Emergent BioSolutions receives $21.5M BioThrax order from Department of War

Emergent BioSolutions Receives Delivery Order up to $21.5 Million to Supply BioThrax® (Anthrax Vaccine Adsorbed) to the U.S. Department of War in 2026

Jan 8, 2026, 4:30 PM EST - 4 months ago

Emergent BioSolutions Receives Delivery Order up to $21.5 Million to Supply BioThrax® (Anthrax Vaccine Adsorbed) to the U.S. Department of War in 2026

Emergent BioSolutions enters collaboration agreement with PANTHER

2026-01-08T13:42:27.000Z - 4 months ago

Emergent BioSolutions enters collaboration agreement with PANTHER

Emergent BioSolutions and PANTHER Announce Agreement to Support the Continuation of the Africa CDC-led MpOx Study in Africa

Jan 8, 2026, 8:00 AM EST - 4 months ago

Emergent BioSolutions and PANTHER Announce Agreement to Support the Continuation of the Africa CDC-led MpOx Study in Africa

Emergent BioSolutions to Present at the 44th Annual J.P. Morgan Healthcare Conference on January 14, 2026

Jan 7, 2026, 7:59 AM EST - 4 months ago

Emergent BioSolutions to Present at the 44th Annual J.P. Morgan Healthcare Conference on January 14, 2026

Emergent BioSolutions Receives U.S. FDA Approval for Drug Product Manufacturing of raxibacumab at its Winnipeg, Canada Site

Dec 12, 2025, 8:30 AM EST - 5 months ago

Emergent BioSolutions Receives U.S. FDA Approval for Drug Product Manufacturing of raxibacumab at its Winnipeg, Canada Site

Emergent BioSolutions Marks 10-Year Anniversary of the U.S. FDA Approval of NARCAN® Nasal Spray and Reinforces its Commitment to Increasing Naloxone Access

Nov 18, 2025, 8:00 AM EST - 6 months ago

Emergent BioSolutions Marks 10-Year Anniversary of the U.S. FDA Approval of NARCAN® Nasal Spray and Reinforces its Commitment to Increasing Naloxone Access

Emergent BioSolutions Announces Retirement of Dr. Louis W. Sullivan from Board of Directors

Nov 12, 2025, 4:01 PM EST - 6 months ago

Emergent BioSolutions Announces Retirement of Dr. Louis W. Sullivan from Board of Directors

Emergent BioSolutions Earnings Call Transcript: Q3 2025

Oct 29, 2025, 5:00 PM EDT - 6 months ago

Emergent BioSolutions Earnings Call Transcript: Q3 2025

Emergent BioSolutions Reports Third Quarter 2025 Financial Results

Oct 29, 2025, 4:15 PM EDT - 6 months ago

Emergent BioSolutions Reports Third Quarter 2025 Financial Results

Emergent BioSolutions Releases New Survey Findings Revealing Heightened Concerns About Biological Threats and U.S. Preparedness

Oct 28, 2025, 8:00 AM EDT - 7 months ago

Emergent BioSolutions Releases New Survey Findings Revealing Heightened Concerns About Biological Threats and U.S. Preparedness

Emergent BioSolutions to Report Third Quarter 2025 Financial Results on October 29, 2025

Oct 8, 2025, 7:45 AM EDT - 7 months ago

Emergent BioSolutions to Report Third Quarter 2025 Financial Results on October 29, 2025

Emergent BioSolutions Recognizes Several Important Observances to Help Save Lives from Opioid Poisoning and Encourages Preparedness with Life-Saving Naloxone

Sep 24, 2025, 4:05 PM EDT - 8 months ago

Emergent BioSolutions Recognizes Several Important Observances to Help Save Lives from Opioid Poisoning and Encourages Preparedness with Life-Saving Naloxone

Emergent BioSolutions Secures $29 Million in MCM Product Orders from International Government Partner

Sep 19, 2025, 8:34 AM EDT - 8 months ago

Emergent BioSolutions Secures $29 Million in MCM Product Orders from International Government Partner

Emergent BioSolutions Secures $17 Million Contract Modification for Oral Suspension TEMBEXA® (brincidofovir), a Smallpox Antiviral, and Strengthens Overall U.S. Supply Chain

Sep 15, 2025, 8:35 AM EDT - 8 months ago

Emergent BioSolutions Secures $17 Million Contract Modification for Oral Suspension TEMBEXA® (brincidofovir), a Smallpox Antiviral, and Strengthens Overall U.S. Supply Chain

Emergent BioSolutions Receives New Contract Modification for ACAM2000®, (Smallpox and Mpox (Vaccinia) Vaccine, Live) from the U.S. Government, Further Demonstrating Importance of Public Health Preparedness

Sep 9, 2025, 7:30 AM EDT - 8 months ago

Emergent BioSolutions Receives New Contract Modification for ACAM2000®, (Smallpox and Mpox (Vaccinia) Vaccine, Live) from the U.S. Government, Further Demonstrating Importance of Public Health Preparedness

Emergent BioSolutions Transcript: Wells Fargo 20th Annual Healthcare Conference 2025

Sep 4, 2025, 3:00 PM EDT - 8 months ago

Emergent BioSolutions Transcript: Wells Fargo 20th Annual Healthcare Conference 2025

Emergent BioSolutions Awarded $30 Million Contract Modification for CYFENDUS® (Anthrax Vaccine Adsorbed, Adjuvanted), a Two-Dose Anthrax Vaccine for Post-Exposure Prophylaxis Use

Sep 2, 2025, 7:40 AM EDT - 9 months ago

Emergent BioSolutions Awarded $30 Million Contract Modification for CYFENDUS® (Anthrax Vaccine Adsorbed, Adjuvanted), a Two-Dose Anthrax Vaccine for Post-Exposure Prophylaxis Use

Emergent BioSolutions Underscores Continued Support of Increasing Naloxone Awareness Through Public Education Campaign on International Overdose Awareness Day

Aug 29, 2025, 8:05 AM EDT - 9 months ago

Emergent BioSolutions Underscores Continued Support of Increasing Naloxone Awareness Through Public Education Campaign on International Overdose Awareness Day

Emergent BioSolutions to Participate in Upcoming Investor Conferences

Aug 27, 2025, 8:01 AM EDT - 9 months ago

Emergent BioSolutions to Participate in Upcoming Investor Conferences

Emergent BioSolutions Supports Voices for Awareness and Facing Fentanyl Now on August 21, 2025 for National Fentanyl Prevention and Awareness Day™

Aug 21, 2025, 8:45 AM EDT - 9 months ago

Emergent BioSolutions Supports Voices for Awareness and Facing Fentanyl Now on August 21, 2025 for National Fentanyl Prevention and Awareness Day™

Emergent BioSolutions Earnings Call Transcript: Q2 2025

Aug 6, 2025, 5:00 PM EDT - 9 months ago

Emergent BioSolutions Earnings Call Transcript: Q2 2025

Emergent BioSolutions Reports Second Quarter 2025 Financial Results

Aug 6, 2025, 4:15 PM EDT - 9 months ago

Emergent BioSolutions Reports Second Quarter 2025 Financial Results

Emergent Applauds Availability of Over-the-Counter Naloxone in U.S. House of Representatives

Jul 28, 2025, 8:50 AM EDT - 10 months ago

Emergent Applauds Availability of Over-the-Counter Naloxone in U.S. House of Representatives

New Publication in Expert Review of Anti-infective Therapy Evaluates Brincidofovir as Potential Antiviral Treatment for Mpox

Jul 28, 2025, 8:50 AM EDT - 10 months ago

New Publication in Expert Review of Anti-infective Therapy Evaluates Brincidofovir as Potential Antiviral Treatment for Mpox

Emergent BioSolutions to Report Second Quarter 2025 Financial Results on August 6, 2025

Jul 15, 2025, 7:30 AM EDT - 10 months ago

Emergent BioSolutions to Report Second Quarter 2025 Financial Results on August 6, 2025

Emergent BioSolutions Secures $51.9 Million Contract Modification Award for CNJ-016® [Vaccinia Immune Globulin Intravenous (Human)] (VIGIV) as part of U.S. Biodefense Preparedness Efforts

Jul 8, 2025, 4:45 PM EDT - 11 months ago

Emergent BioSolutions Secures $51.9 Million Contract Modification Award for CNJ-016® [Vaccinia Immune Globulin Intravenous (Human)] (VIGIV) as part of U.S. Biodefense Preparedness Efforts

Emergent BioSolutions Expands NARCANDirect® to Offer KLOXXADO® (naloxone HCl) Nasal Spray 8 mg and Convenience Kits Amid Changes in Overdose Death Rate

Jul 2, 2025, 4:05 PM EDT - 11 months ago

Emergent BioSolutions Expands NARCANDirect® to Offer KLOXXADO® (naloxone HCl) Nasal Spray 8 mg and Convenience Kits Amid Changes in Overdose Death Rate

Emergent BioSolutions Secures $62.4 Million Contract Modification for BAT® [Botulism Antitoxin Heptavalent (A, B, C, D, E, F, G) – (Equine)] to Bolster U.S. Biodefense Supply

Jun 23, 2025, 8:05 AM EDT - 11 months ago

Emergent BioSolutions Secures $62.4 Million Contract Modification for BAT® [Botulism Antitoxin Heptavalent (A, B, C, D, E, F, G) – (Equine)] to Bolster U.S. Biodefense Supply

Emergent BioSolutions Announces Addition to Russell 3000® Index

Jun 20, 2025, 8:13 AM EDT - 11 months ago

Emergent BioSolutions Announces Addition to Russell 3000® Index

Emergent BioSolutions Transcript: Jefferies Global Healthcare Conference 2025

Jun 5, 2025, 1:25 PM EDT - 1 year ago

Emergent BioSolutions Transcript: Jefferies Global Healthcare Conference 2025

Emergent BioSolutions Supports Victoria's Voice Foundation's National Naloxone Awareness Day Efforts on June 6 to Encourage Americans to Be Prepared for Opioid Emergencies

Jun 5, 2025, 7:00 AM EDT - 1 year ago

Emergent BioSolutions Supports Victoria's Voice Foundation's National Naloxone Awareness Day Efforts on June 6 to Encourage Americans to Be Prepared for Opioid Emergencies

Emergent BioSolutions Transcript: RBC Capital Markets Global Healthcare Conference 2025

May 20, 2025, 3:35 PM EDT - 1 year ago

Emergent BioSolutions Transcript: RBC Capital Markets Global Healthcare Conference 2025

Emergent BioSolutions Earnings Call Transcript: Q1 2025

May 7, 2025, 5:00 PM EDT - 1 year ago

Emergent BioSolutions Earnings Call Transcript: Q1 2025

Emergent BioSolutions Reports First Quarter 2025 Financial Results

May 7, 2025, 4:05 PM EDT - 1 year ago

Emergent BioSolutions Reports First Quarter 2025 Financial Results

Emergent BioSolutions Reinforces Commitment to Opioid Emergency Preparedness Efforts in Canada Through Multi-Year Contract with Ontario Ministry of Health

May 1, 2025, 5:07 PM EDT - 1 year ago

Emergent BioSolutions Reinforces Commitment to Opioid Emergency Preparedness Efforts in Canada Through Multi-Year Contract with Ontario Ministry of Health

Emergent BioSolutions to Report First Quarter 2025 Financial Results on May 7, 2025

Apr 22, 2025, 8:00 AM EDT - 1 year ago

Emergent BioSolutions to Report First Quarter 2025 Financial Results on May 7, 2025

ComradeKomisar
ComradeKomisar May. 13 at 3:31 PM
$EBS judging from the spikes in borrow rates at IBKR, shorting frequency has been super agressive since last opex. However, they never managed to get it below the 'breakup' price which is 8-ish.
0 · Reply
ImmxBeliever
ImmxBeliever May. 13 at 3:30 PM
$EBS
0 · Reply
billywilliamz
billywilliamz May. 13 at 3:27 PM
$EBS 6. Fiddy
0 · Reply
ComradeKomisar
ComradeKomisar May. 13 at 3:24 PM
$EBS Big account in X (86K followers)
0 · Reply
BavarianStallion
BavarianStallion May. 13 at 3:15 PM
$EBS can someone explain why we the management doesn‘t do buybacks on such days like hell?
0 · Reply
Unicorn2020
Unicorn2020 May. 13 at 2:14 PM
$EBS This sucker seems to get dragged back down to fill the lower gap at $6.30. Give it 90 days. It will get there.
0 · Reply
ComradeKomisar
ComradeKomisar May. 13 at 1:53 PM
$EBS Having to sell the travel vaccine portfolio was an absolute fumble by this management (the board is effectively new, so the blame passes over).
2 · Reply
ComradeKomisar
ComradeKomisar May. 13 at 1:22 PM
$EBS Gut niewuss, Jane St., a most vile shop, is almost out.
0 · Reply
billywilliamz
billywilliamz May. 13 at 1:21 PM
$EBS is this a lot ?
0 · Reply
ComradeKomisar
ComradeKomisar May. 13 at 1:19 PM
$EBS Regrettably, they/them/those ...covered.
0 · Reply
thecryptofire
thecryptofire May. 13 at 9:26 AM
$BTC $MRNA $EBS $BNTX Michael Saylor says Strategy may buy 10 to 20 more Bitcoin for every BTC sold as the company pushes deeper into long-term accumulation. https://www.thecryptofire.com/p/saylor-says-strategy-could-buy-20-btc-for-each-sold
0 · Reply
billywilliamz
billywilliamz May. 13 at 12:12 AM
$EBS y down ? Lol
1 · Reply
ComradeKomisar
ComradeKomisar May. 12 at 8:26 PM
$EBS Basically. The trip to $9.66 was due to this Hanta thing. Re-donkey-lous, but it is how it is.
0 · Reply
alwayzwong
alwayzwong May. 12 at 5:20 PM
$EBS filled the gap from 5/5
0 · Reply
ImmxBeliever
ImmxBeliever May. 12 at 5:10 PM
$EBS
0 · Reply
Daniel3303
Daniel3303 May. 12 at 5:00 PM
$EBS Short pressure exhausted, time to buy the bottom
0 · Reply
ComradeKomisar
ComradeKomisar May. 12 at 4:01 PM
$EBS Overstock issued blockchain based preferred shares dividend that could only trade in its own blockchain, that the shorties could never get/find. This company is a dinosaur compared to Overstock. The CEO is over 70 years old, and did not manage to shake up internal ranks.
1 · Reply
Daniel3303
Daniel3303 May. 12 at 3:51 PM
$EBS If management issues a non cash dividend that shorts can not replicate, they are trapped. Something like what Overstock did a few years ago can happen with EBS. A precedent was created, shorts lost in court against Overstock
0 · Reply
Daniel3303
Daniel3303 May. 12 at 3:48 PM
$EBS Current short interest is over 20%. With recent volume it would take more than 20 days to cover.
0 · Reply
ComradeKomisar
ComradeKomisar May. 12 at 2:41 PM
$EBS Removing that stupid Q1 '25 $60M MCM order with $50M margin, the normalized picture of this company's ops looks quite benign Q/Q. I suspect that in 2025, they brought forward future MCM demand in order to have some cushion for OHA covenant purposes. This kind of event can randomly happen again, resulting in surprise guidance raises.
0 · Reply
Daniel3303
Daniel3303 May. 12 at 2:35 PM
$EBS Short sellers manipulating the price due to low volume. They are digging a whole. Yesterday we had the second most shorted day in the past 2 weeks.
0 · Reply
ComradeKomisar
ComradeKomisar May. 12 at 12:40 PM
$EBS 13F filings trickling in. In today's report, 11 filers representing 2.6M shares are showing a net increase in holdings.
0 · Reply